- €75.15m
- €372.31m
- €786.44m
Brief: Guerbet Q3 Revenue Up At EUR 187 Mln
Brief: Guerbet Gets EUR 1 Mln Of Public Funding From Bpifrance
Brief: Guerbet Announces FDA Approval Of Elucirem™ (Gadopiclenol)
Brief: Guerbet H1 EBITDA Down At EUR 50.5 Mln
Brief: Guerbet H1 Sales Rise To EUR 371.1 Million
Brief: Guerbet Receives EMA Acceptance Of Elucirem As The Brand Name For Gadopiclenol
Brief: Guerbet Q1 Revenue Up At EUR 181.1 Mln
Brief: Gadopiclenol Marketing Authorization Dossier Submissions Accepted For Review By EMA And FDA
Brief: Guerbet Says EMA, FDA Agree To Review Gadopiclenol Marketing Authorisation
Brief: Guerbet Eyes Revenue Increase Of 2%-4% LFL In 2022
Brief: Guerbet Q4 Revenue Up At 191.1 Million Euros
Brief: Guerbet, Bracco Imaging Sign Global Strategic Collaboration Agreement For Gadopiclenol
Brief: Guerbet Q3 Sales Up At Eur 177.9 Million
Brief: Guerbet Contributes To NH TherAguix IPO By Placing Order Of €3 million
Brief: Guerbet H1 Operating Income Up At EUR 34.8 Mln
Brief: Guerbet Q2 Revenue At EUR 186.8 Mln
Brief: Guerbet Says Marc Massiot Appointed To BOD
Brief: Guerbet Q1 Revenue Down 11.5% At 176.3 Million Euros
Brief: Guerbet: South African Health Products Regulatory Authority Approves Lipiodol Ultra-Fluid